Guardant Health News: Company Announces FDA Approval of Liquid Biopsy Test
Guardant Health, a leading precision oncology company, recently announced that their advanced liquid biopsy test has received approval from the United States Food and Drug Administration (FDA). This announcement has been making waves in the medical community, as it is seen as a major breakthrough in cancer treatment.
What is a Liquid Biopsy Test?
A liquid biopsy is a non-invasive diagnostic test that detects cancer cells or DNA fragments that are circulating in the bloodstream. This type of test is particularly useful for patients who are unable or unwilling to undergo surgery or other invasive procedures. The liquid biopsy test allows doctors to monitor the progression of cancer in real-time and make better-informed decisions about treatment.
How Does Guardant Health’s Liquid Biopsy Test Work?
Guardant Health’s liquid biopsy test, called Guardant360, uses next-generation sequencing (NGS) technology to analyze a patient’s blood sample. The test looks for specific genetic mutations and other biomarkers that are associated with certain types of cancer. Guardant360 can identify mutations in more than 70 genes and can detect cancer cells with a sensitivity of 99.9 percent.
Why is FDA Approval Significant?
The FDA approval of Guardant360 is significant because it validates the accuracy and reliability of the liquid biopsy test. It also opens the door for more widespread adoption of the test by healthcare providers and insurance companies. Additionally, the FDA’s approval could increase the chances of insurance companies covering the cost of the test, making it more accessible to patients.
What are the Benefits of Guardant360?
Guardant360 has several benefits over traditional biopsy methods. The test is non-invasive, which means patients can avoid the discomfort and risks associated with surgical biopsies. Additionally, Guardant360 is more comprehensive than traditional biopsies, as it can detect multiple genetic mutations and biomarkers at once. This allows doctors to make more informed decisions about treatment options and monitor the progression of cancer more effectively.
Conclusion
The FDA approval of Guardant Health’s liquid biopsy test is a major milestone in the fight against cancer. The test has the potential to revolutionize cancer treatment and make it more accessible to patients. Healthcare providers, insurance companies, and patients alike should welcome this new development and embrace the benefits of this innovative technology.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.